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Atherosclerosis is a complex process characterized by an
increase in the wall thickness owing to the accumulation of
cells and extracellular matrix between the endothelium and
the smooth muscle cell wall. This process is associated with
different pathologies and it is accelerated in patients with
chronic renal failure. In these patients, decreased synthesis of
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) leads to secondary
complications, like hyperparathyroidism, and treatment with
1,25(OH)2D3 is a common practice. The effect of 1,25(OH)2D3
on vascular smooth muscle cells (VSMCs) calcification has
been widely studied, but the role of 1,25(OH)2D3 on VSMC
proliferation remains obscure. We have analyzed the effects
of 1,25(OH)2D3 in the proliferation of VSMC. We found that
1,25(OH)2D3 (5–100 nM) induces a dose-dependent increase in
VSMC proliferation in quiescent cells and in cells stimulated
to grow. This increase in proliferation is achieved by
shortening the G1 phase. The effect of 1,25(OH)2D3 on VSMC
proliferation is mediated by an increase of the expression of
vascular endothelial growth factor A (VEGF), as the inhibition
of VEGF activity totally blunted the 1,25(OH)2 D3-induced
VSMC proliferation. We found this increase in proliferation in
vitro, ex vivo in aortic rings incubated with 1,25(OH)2D3, and
in vivo in animals with a model of chronic renal failure (5/6
nephrectomy) treated with 1,25(OH)2D3 (1 lg/kg three times
a week for 8 weeks). Thus, we conclude that 1,25(OH)2D3
induces increases in VSMC proliferation through an increase
on VEGF expression.
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Patients with chronic kidney disease (CKD) and dialysis
patients show an increased mortality despite measures to
optimize the dialysis treatment.1,2 One of the causes of this
increase in mortality seems to be related to changes in the
cardiovascular system.3,4 Lindner et al.5 concluded that
accelerated atherosclerosis, with proliferation of vascular
smooth muscle cells (VSMCs), was the major cause of this
increased cardiovascular mortality. However, in patients with
CKD, another arteriopathy has been described, characterized
by an increase in the thickness of the arterial wall with
intimal proliferation and endovascular fibrosis with calcifica-
tion.6,7 This arteriosclerotic process leads to a stiffening of the
arteries, abnormal coronary perfusion, and left ventricular
hypertrophy.8 Thus, unregulated proliferation of VSMC may
play a central role in both arteriopathies. Under normal
circumstances, VSMCs have very reduced proliferation rates,
but different physiopathological stimuli can induce their
growth.9 A number of factors have been involved in the
calcification process,10,11 but the mediators involved in
VSMC proliferation are unknown.
In CKD, impaired production of 1,25-dihydroxyvitamin
D3 (1,25(OH)2D3), is a major contributor to the occurrence
of parathyroid hyperplasia and to the increased synthesis and
secretion of parathyroid hormone. Thus, 1,25(OH)2D3 is
widely used to treat secondary hyperparathyroidism. Several
studies have demonstrated that an excess of 1,25(OH)2D3 is
arteriotoxic12 and that 1,25(OH)2D3 induces vascular
calcifications in humans and experimental animals.13,14 Thus,
the effects of 1,25(OH)2D3 on vascular calcification have been
widely studied, but its effects on vascular cell proliferation
remain unclear. Furthermore, the presence of vitamin D
receptor (VDR) in endothelial cells and VSMCs, and the
finding that endothelial cells synthesize 1,25(OH)2D3 raises
new questions about its paracrine role.15,16 Recent studies
suggest that 1,25(OH)2D3 may have further implications in
the atherosclerotic process. In this line of reasoning, Zhender
et al.16 postulated that the synthesis of 1,25(OH)2D3 by
endothelial cells has a paracrine/autocrine function and acts
at a local level promoting leukocyte adhesion. Furthermore,
Rebsamen et al.17 found that 1,25(OH)2D3 induced a dose-
dependent increase in VSMC migration.
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Although it is known that 1,25(OH)2D3 acts on many cell
lines to decrease the proliferation rate, the few studies aimed
at analyzing the effect of 1,25(OH)2D3 on VSMCs showed
controversial results.18,19 Therefore, we decided to investigate
whether 1,25(OH)2D3 exerts an effect on VSMC proliferation
in vitro, in aortic rings ex vivo, and in a model of CKD in rats.
We also analyzed the mediators involved in this process.
RESULTS
Effect of 1,25(OH)2D3 on VSMC proliferation
We investigated the effect of crescent concentrations of
1,25(OH)2D3 (5–100 nM) on proliferation of serum-starved
VSMCs. 1,25(OH)2D3 stimulated VSMC proliferation in a
dose-dependent manner (Figure 1a).
To determine if 1,25(OH)2D3 could increase the pro-
liferative effect induced by growth factors, quiescent cells
were treated for 24 h with basic fibroblast growth factor
(bFGF) (20 ng/ml) with increasing concentrations of
1,25(OH)2D3 (5–100 nM). Figure 1b shows that
1,25(OH)2D3 increased proliferation in a dose-dependent
manner, with significant stimulatory effects at doses as low as
5 nM. Then, we tested the effect of fetal bovine serum (FBS)
addition to the 1,25(OH)2D3-induced proliferation. As
expected, FBS had a strong effect on the proliferation and,
at high concentrations, FBS was able to mask the effects
mediated by 1,25(OH)2D3 (Figure 1c).
We decided to perform flow cytometry analysis to further
characterize the effect of 1,25(OH)2D3 on VSMC prolifera-
tion by bFGF. Fluorescence-activated cell sorter analysis
showed an increase in the percentage of cells in S phase in the
1,25(OH)2D3-treated culture, indicating that 1,25(OH)2D3
advanced S-phase entry by 6 h (Figure 2).
Then, we examined the effect of 1,25(OH)2D3 on VSMC
proliferation in aortic rings ex vivo (Figure 3). 1,25(OH)2D3
induced an increase in proliferating cells with respect to the
control. These cells were identified as VSMCs by labeling for
a-actin.
Finally, the effect of 1,25(OH)2D3 in vivo was assessed in a
model of CKD. Animals with 5/6 renal mass reduction and
treated with 1,25(OH)2D3 for 8 weeks did not gain weight
during the treatment (200724 g), whereas animals treated
with saline increased their weight (280720 g). Total calcium
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Figure 1 | Effects of 1,25(OH)2D3 on VSMC proliferation. VSMCs
were made quiescent by serum starvation (0.2% FBS) for 48 h, then
cells were treated with increasing concentrations of 1,25(OH)2D3 for
another 48 h in the (a) absence or (b) presence of 20 ng/ml of bFGF.
Cell proliferation was assayed by BrdU incorporation with an enzyme-
linked immunosorbent assay technique. (c) Crescent concentrations
of serum were added to the culture media of cells incubated with
(100 nM) (open bars) or controls (dashed bars). Bars represent
means7s.e.m. of three independent experiments. #Po0.05, *Po0.01
vs 0 nM; wPo0.01 vs no 1,25(OH)2D3 and same serum concentration.
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Figure 2 | Analysis of cell cycle progression in VSMCs treated with 1,25(OH)2D3. Quiescent cells stimulated to grow with bFGF were
incubated with or without 100 nM 1,25(OH)2D3 for 22 h. DNA content distributions were determined by fluorescence-activated cell sorter
analysis at 0, 16, and 22 h. The percentages of cells in S phase are shown.
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levels were significantly increased in animals receiving
1,25(OH)2D3 compared with control animals (control:
11.0270.14 mg/dl; 1,25(OH)2D3: 12.1470.3 mg/dl. Po0.01).
We also observed an increase in phosphate levels that did not
reach statistical significance (control: 6.0670.27 mg/dl;
1,25(OH)2D3: 6.6870.35 mg/dl). In addition, levels of calcium
phosphorous product (CaXPO4) product were significantly
higher in rats receiving 1,25(OH)2D3 compared with control
animals (control: 66.8373 mg2/dl2; 1,25(OH)2D3: 81.37
5.2 mg2/dl2; Po0.01). Animals with 5/6 renal mass reduction
presented a decreased creatinine clearance (control: 1.670.19;
5/6 nephrectomy: 1.04770.17 ml/min). Treatment with
1,25(OH)2D3 further aggravated the renal failure (5/6
nephrectomyþ 1,25(OH)2 D3: 0.5870.09 ml/min; Po0.05
vs 5/6 nephrectomy). Animals with 5/6 renal mass reduction
and treated with 1,25(OH)2D3 for 8 weeks had a higher
number of proliferative nuclei (stained for Ki67) than animals
untreated (3J). The proliferative cells were identified as VSMC
by a-actin immunofluorescence.
Effect of 1,25(OH)2D3 on gene expression in VSMCs
Treatment with 1,25(OH)2D3 significantly increased the VDR
mRNA levels in VSMC (Figure 4a). Results of the Western
blot analysis showed that VDR protein increased by more
than 10-fold after 12 h of treatment (Figure 4b).
In Figure 4, we show the effects of 1,25(OH)2D3 treatment
in VSMC on vascular endothelial growth factor A (VEGF)
mRNA and protein expression. We found that treatment with
1,25(OH)2D3 significantly increased the levels of VEGF
mRNA and protein (Figure 4c and d). The expression of
fms-like tyrosine kinase 1 (FLT-1) receptor was slightly
increased by real-time polymerase chain reaction (PCR) and
Western blot (Figure 4e and f). No expression of FLK-1 was
detected either by real-time PCR or Western Blot.
To determine if an increase in VEGF was responsible for
the increase in proliferation, we incubated VSMC with
1,25(OH)2D3 and a VEGF receptor antagonist (VGA1102). In
Figure 5a, we can see that co-incubation with VGA1102
totally blunted the proliferative effect induced by 1,25(OH)2
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Figure 3 | Immunofluorescence analysis of the proliferative effect of 1,25(OH)2D3 on VSMC in aortic rings ex vivo and in vivo. Explants
were cultured in DMEM–20% FBS for 8 days, then medium was replaced and BrdU at 10 mM was added. Explants were then incubated with or
without 100 nM 1,25(OH)2D3 for 4 days. Immunofluorescence of BrdU-positive nucleus was performed in aortic ring sections (green), total
nucleus was stained with Hoechst 33342 (blue), and VSMC were identified by a-actin immunofluorescence (red). (a and b) Explants control
(original magnification,  30) (c and d) Explants treated with 1,25(OH)2D3 (original magnification,  60). Animals with 5/6 nephrectomy were
treated with 1 mg/kg of 1,25(OH)2D3 three times a week for 8 weeks or with a saline injection. Aortas were included in paraffin and sliced.
Immunofluorescence of Ki67-positive nucleus was performed in aortic ring sections (green), total nucleus was stained with Hoechst 33342
(blue), and VSMC were identified by a-actin immunofluorescence (red). (e and f) Immunofluorescence of aorta samples of control rats and
(original magnification,  30) (g and h) rats treated with 1,25(OH)2D3 (original magnification,  30). (i) Quantification of the proliferation
induced by 1,25(OH)2D3 on aortic explants ex vivo. (j) Quantification of the proliferation induced by 1,25(OH)2D3 on aortic sections in vivo. Bars
represent means7s.e.m. (n¼ 10 sections). *Po0.01 vs control.
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D3. No toxic effect was detected in VSMC at the dose used
(Figure 5b).
We also incubated VSMC with 1,25(OH)2D3 and VEGF-
neutralizing antibody. The addition of the antibody elimi-
nated the increase in proliferation induced by 1,25(OH)2D3
(Figure 5c).
DISCUSSION
The biological actions of 1,25(OH)2D3 are mediated by its
specific receptor, the VDR.20 Therefore, to study the effect of
1,25(OH)2D3 in VSMCs, first we determined whether
VSMCs show a functional and coherent response to vitamin
D. It has been described that VDR levels are upregulated by
1,25(OH)2D3.
21 We have found that 1,25(OH)2D3 increased
VDR mRNA and protein levels in VSMC, indicating that the
VDR pathway is fully functional in these cells. The content of
VDR is a very important factor in the transcriptional activity
in target cells. An increase in VDR number could ‘sensitize’
vascular cells to vitamin D action, as it occurs in other tissues
(parathyroid glands, bowel mucosa, etc.).22,23 However,
increases in VDR could also stimulate the expression of
24-hydroxylase, the enzyme that initiates the degradation of
1,25(OH)2D3, in order to regulate its local concentrations
and, therefore, the response to 1,25(OH)2D3. In addition, in
this work, we have found that 1,25(OH)2D3 has a clear
proliferative effect. As the first report stating that
1,25(OH)2D3 inhibited proliferation and induced the differ-
entiation of murine myeloid leukemia M1 cells into
monocyte macrophages,24 many studies have demonstrated
that 1,25(OH)2D3 is a potent suppressor of proliferation and
an inductor of the differentiation in numerous cells
types.25,26 However, the few studies aimed at analyzing the
effect of 1,25(OH)2D3 on VSMC proliferation showed
conflictive results, most likely owing to the different
experimental conditions used.18,27 Furthermore, the discov-
ery of the VDR in VSMC raises new questions about its
function in this particular cell type. We have used quiescent
cells to prevent saturating effects of other growth factors.
Furthermore, no serum was added in the experiment. This is
particularly important because it demonstrates that
1,25(OH)2D3 alone, in the absence of any other stimuli, is
able to induce an increase in VSMC proliferation. Thus, the
effect of 1,25(OH)2D3 on VSMC proliferation is direct, and
independent of serum-related factors.
In a second approach, the effect of 1,25(OH)2D3 on the
proliferation of VSMC already stimulated to grow was
assessed. We found that the effects of 1,25(OH)2D3 were
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Figure 4 | VDR and VEGF expression and protein levels in VSMCs
treated with 1,25(OH)2D3. Total RNA was isolated at 0, 16, and 24 h
after treatment with or without 100 nM 1,25(OH)2D3. Expression levels
of (a) VDR, (c) VEGF, and (e) FLT-1 (16 h after 1,25(OH)2D3 addition)
were analyzed by real-time reverse transcriptase-PCR. Average values
and s.e.m. of three independent experiments are shown. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was used as an
internal control. Total protein was isolated from VSMCs treated with
or without 100 nM 1,25(OH)2D3 at specific time points. A representa-
tive Western blot for (b) VDR or (f) FLT-1 is shown. (d) VEGF levels
were determined by enzyme-linked immunosorbent assay in the
supernatant of control cells and treated with 1,25(OH)2D3 (100 nM).
Average values and s.e.m. of three independent experiments are
shown. *Po0.01 vs control.
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Figure 5 | Effect of VEGF receptor antagonist (VGA1102) and
VEGF-neutralizing antibody on proliferation induced by
1,25(OH)2D3. VSMCs were cultured in DMEM–0.2% FBS with 100 nM
1,25(OH)2D3 and with or without 1 mM VGA1102 or antibody against
a-VEGF (0.6 mg/ml). BrdU incorporation was detected with an
enzyme-linked immunosorbent assay technique to determine cell
proliferation on cells treated with (a) VGA 1102 or antibody against
(c) a-VEGF. (b) The effect of 1 mM VGA1102 on cell viability was
analyzed using the MTT test. Bars represent means7s.e.m. of three
independent experiments. *Po0.01 vs non-treated cells. #Po0.01 vs
cells treated with 1,25(OH)2D3.
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additive to those of bFGF, demonstrating that the effect of
1,25(OH)2D3 on VSMC proliferation is not dependent on the
status of the cell (quiescent vs not quiescent). Thus, in
pathological conditions in which VSMCs are already
stimulated to grow, the addition of 1,25(OH)2D3 could lead
even to a higher increase of the proliferation rate. This could
be especially important in patients with CKD, in which
treatment with 1,25(OH)2D3 is a common medical practice.
It is known that patients with CKD have an increase in
VSMC proliferation, leading to arterial complications and
uremic arteriopathy.6 Therefore, treatment with
1,25(OH)2D3 could lead to a further stimulus in VSMC
proliferation.
In a third approach, we added crescent amounts of serum
to the cells stimulated with 1,25(OH)2D3. In this case,
1,25(OH)2D3 was not able to increase further proliferation
rates when cells were strongly stimulated to proliferate by
high concentrations of serum. However, 1,25(OH)2D3 was
able to increase the proliferation rate in cells incubated with
lower levels of serum. This could be explained by the fact that
cells incubated in vitro have a differential uptake of
1,25(OH)2D3 compared to that of VSMCs surrounded by
an intact arterial structure.
A further evidence of the increase in proliferation induced
by 1,25(OH)2D3 was obtained by fluorescence-activated cell
sorter analysis. Our results indicate that VSMCs enter S phase
earlier in the presence of 1,25(OH)2D3, suggesting that the
higher proliferation rates caused by 1,25(OH)2D3 are
probably owing to a shortening of the G1 phase.
These in vitro results must be taken with caution, because
of the absence of inhibitory factors present in the in vivo
situation, when other cell types are present. However, the
proliferative effect of 1,25(OH)2D3 has also been demon-
strated ex vivo in arterial rings and in vivo in animals with
CKD. This in vivo effect could also be an indirect effect
mediated by the increase in serum calcium and phosphate
levels. Nevertheless, we must point out that the doses uses in
vivo in our experimental settings are higher than the ones
used in patients, reflecting the effect of 1,25(OH)2D3
overdosing. Extrapolating this effect to the clinical field,
1,25(OH)2D3 might be an important mediator of arterial
remodelling induced by atherogenic factors, direct injury,
uremia, and hemodynamic burden. Furthermore, the fact
that VDR is upregulated by 1,25(OH)2D3 in VSMC raises
new concerns. Thus, if 1,25(OH)2D3 is overdosed in chronic
renal failure28 or osteoporosis,29 the beneficial effects of the
therapy might be shadowed by an increase of the suscep-
tibility of vessels to 1,25(OH)2D3-induced proliferation.
The concentration of 1,25(OH)2D3 used in this study
(5–100 nM) is higher than the normal serum levels, but it falls
within the range which induces biological response in other
tissues and cell types analyzed in vitro.18,30–33 Furthermore, in
the clinical settings, the levels of 25-hydroxyvitamin D are
used to determine the vitamin D status. The normal range of
25-hydroxyvitamin D-circulating levels is 40–180 nM. Thus,
knowing that endothelial cells possess the capacity to
transform 25-hydroxyvitamin D in 1,25(OH)2D3 and that
this activity seems to be only related to substrate avail-
ability,16 we can suggest that local levels at the vascular bed
could be much higher than in serum. Furthermore, in renal
failure, extrarenal synthesis and degradation of 1,25(OH)2D3
seems to be altered. Dusso et al.34 demonstrated that
macrophages showed an increased synthesis of
1,25(OH)2D3 in uremic conditions. Gallieni et al.
35 showed
that monocytes also had an increase 1-a hydroxylase activity
in uremia. In addition, Hsu et al.36 studied the effect of
uremic toxins on 24 and 25 hydroxylase activities. This study
concluded that, in uremic conditions, metabolic degradation
of 1,25(OH)2D3 is decreased. There is no direct evidence that
the synthesis of 1,25(OH)2D3 by endothelial cells is increased
in renal failure. However, it has been published that the
synthesis of 1,25(OH)2D3 by human endothelial cells is
increased by inflammatory cytokines16 and that in renal
failure there is a systemic inflammatory condition with an
increase in tumor necrosis factor-a and interleukin-8.16,37 In
addition, advanced glycation end products, which accumu-
late in renal failure, increase tumor necrosis factor-a
expression in endothelial cells.16,38 Thus, in renal failure
conditions, the endothelial synthesis of 1,25(OH)2D3 could
be increased, leading to high local levels.
There is now a consensus that VEGF is crucial in
pathological processes both in embryo and in adults.
Alterations of VEGF expression have been involved in several
pathologies, like tumor growth,39 pre-eclampsia,40 etc.
Furthermore, a recent paper stated the involvement of VEGF
in neointimal proliferation in pig arteries following stent
implantation.41 Also, Parenti et al.42 demonstrated that
VSMC proliferation induced by monocyte chemoattractant
protein-1 was mediated by endogenous production of VEGF-A.
Taken together, these results show that VSMC can both
produce and respond to VEGF. Our results also indicate that
1,25(OH)2D3 induces an increase in the expression of VEGF.
These results are in agreement with those of Yamamoto
et al.,43 which showed an increase in VEGF release from a
stable line of smooth muscle cells in culture. Furthermore,
VSMC express VEGF receptors,44 making them a possible
target for the effects of VEGF. We also found that the
addition of the VEGF receptor-binding antagonist
VGA110245 or VEGF-neutralizing antibodies blunted the
increase in 5-bromo-20-deoxy-uridine (BrdU) incorporation
levels in 1,25(OH)2D3-stimulated cells, suggesting that
1,25(OH)2D3-induced VSMC proliferation is mediated by
VEGF.
The mechanism by which 1,25(OH)2D3 increases VEGF
production in VSMC is not clear, but the presence of a
sequence that resembles the DR3 type of vitamin D-res-
ponsive elements46 in the promoter of the rat VEGF gene
may provide an explanation. Further experiments are needed
to determine whether this sequence binds VDR and enhances
transcription in a vitamin D-dependent manner.
As VSMCs play a key role in the development of vascular
pathologies with great impact on mortality, we found it
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necessary to clarify the role of 1,25(OH)2D3 on VSMC
proliferation. This work demonstrates that VSMCs respond
to 1,25(OH)2D3 increasing the proliferation rate through
a VEGF-mediated pathway, suggesting that vitamin D may
be an important mediator of arterial physiopathology.
We also showed that treatment with high doses of
1,25(OH)2D3 in vivo induces an increase in the proliferation
of VSMC in animals with a model of chronic renal failure.
This suggest that 1,25(OH)2D3 overdosing in patients with
chronic renal failure could lead to an increase in VSMC
proliferation.
Whether this increase in proliferation will be deleterious
or beneficial needs further investigation. The increase of
VSMC proliferation in vivo could be a way of attenuating the
apoptotic process observed in high resorptive bone condi-
tions produced with high parathyroid hormone or
1,25(OH)2D3 levels. These apoptotic bodies act as inducers
of calcium deposition and are the main cause of calcification
of the vasculature.47 Therefore, the increase in proliferation
of the adjacent VSMC could reduce the space occupied by the
apoptotic bodies and, thus, the calcified area. This could
partly explain the recently reported increase in survival
observed in dialysis patients treated with 1,25(OH)2D3.
48
Furthermore, control of VSMC proliferation is only one of
the many effects of 1,25(OH)2D3 on the vasculature.
Therefore, the beneficial effects of 1,25(OH)2D3 in the
cardiovascular system, like the modulation of hypertension
and inflammatory responses, could overcome the potential
deleterious effects and provide an overall protection to the
patient. Nonetheless, the impact of 1,25(OH)2D3 on VSMC
proliferation is a potential disadvantage on 1,25(OH)2D3
therapy. The use of vitamin D analogs that retain the
beneficial effects and have no impact on VSMC proliferation
could shed some light on the complex role of vitamin D in
the cardiovascular system.
MATERIALS AND METHODS
All the experiments performed in this study followed the National
Institute of Health Guide for the Care and Use of Laboratory
Animals.
VSMC culture and extraction of aortic rings
Primary aortic VSMCs of 2-month-old Sprague–Dawley rats were
obtained by explants culture as described previously49 and
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% FBS, 100 U/ml penicillin and 100 mg/ml strepto-
mycin.
Cells obtained by this method were identified as VSMCs by the
following criteria: (1) the cells grew in the characteristic hill and
valley pattern and (2) by positive immunostaining for monoclonal
anti-a-smooth muscle actin (Sigma-Aldrich, St Louis, MO, USA).
Primary cultures with less than 95% VSMCs were discarded.
To enrich the population in G0/G1 before each experiment, cells
were serum starved for 2 days in DMEM with 0.2% FBS.
In order to obtain the aortic rings, abdominal aortas were
extracted from Sprague–Dawley rats and stored in ice-cold sterile
phosphate-buffered saline. After three washes with phosphate-
buffered saline and excision of lateral vessels, aortic rings of 2–4 mm
wide were cut and placed in culture plates.
CKD animal model
Sprague–Dawley rats were anesthetized with isoflurane and right
nephrectomy was performed. After 1 week, animals suffered 2/3
nephrectomy in the left kidney by excision of both poles. Animals
with 5/6 nephrectomy were divided into two groups. One group
received 1,25(OH)2D3 (1 mg/kg three times a week for 8 weeks),
whereas the second group received a saline injection. The day before
euthanasia, blood and 24 h urine was collected.
After being killed, abdominal aortas were collected, fixed,
included in paraffin, and sliced.
Biochemistry data
Blood obtained at the end of the experiment was analyzed for
calcium, phosphate, and creatinine levels. Serum and urine
biochemistries were analyzed using a multichannel autoanalyzer
(Roche/Hitachi Modular Analytics, Somerville, NJ, USA). The
method used for creatinine, calcium, and phosphate were the Jaffe´
reaction, the o-cresolphthalein complexone method, and the
ammonium molybdate method, respectively.
Analysis of VSMC proliferation
To test whether VSMC growth might be stimulated by 1,25(OH)2D3
(Sigma-Aldrich), we analyzed the rate of DNA synthesis by BrdU
incorporation and fluorescence-activated cell sorter analysis. VSMCs
were serum starved for 48 h and then stimulated with 1,25(OH)2D3
at 5, 10, 20, and 100 nM in DMEM–0.2% FBS. In some experiments,
the effect of the addition of FBS in the proliferation of VSMC
induced by 1,25(OH)2D3 was also tested. In some of the wells, we
added a new VEGF receptor inhibitor (VGA1102, 1 mM)45 and in
others we added neutralizing VEGF antibody (0.6 mg/ml; R&D
systems, Minneapolis, MN, USA) to eliminate the effect of VEGF in
the proliferation induced by 1,25(OH)2D3. The possible toxic effect
of the VGA1102 in VSMC was tested by MTT (3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide) assay.
Also, quiescent cells were stimulated for 24 h with 20 ng/ml bFGF
and with or without 1,25(OH)2D3 at 5, 10, 20, and 100 nM to test for
a possible additive effect in cells already stimulated to proliferate.
Furthermore, aortic rings were incubated for 72 h in
DMEM–20% FBS with or without 100 nM of 1,25(OH)2D3 and
proliferation was assessed by BrdU incorporation.
BrdU incorporation. Cells were cultured in 96-well plates
(4 103 cells/well) under the conditions described above and
incubated with 10 mM BrdU for 6 h. BrdU incorporation into DNA
was detected using a commercial kit (Roche Diagnostics, Somerville,
NJ, USA).
BrdU incorporation in aortic rings was assessed by immuno-
fluorescence. BrdU was added to the wells 24 h before 1,25(OH)2D3
addition. Rings were fixed with 4% paraformaldehyde, included in
paraffin, and sliced in 4 mm sections. After blocking, incubation with
primary antibody anti-BrdU (1:200; DakoCytomation, Glostrup,
Denmark) was performed overnight at 41C. Secondary antibody
(1:200; Molecular Probes, Eugene, OR, USA) was added for 1 h at
room temperature. Slides were mounted with antifade (Molecular
Probes) and 1% Hoechst-33342 and visualized using a fluorescence
microscope (LEICA Microsystems DFC 480). Proliferation rates
were determined as the percentage of positive nuclei for BrdU per
total nuclei.
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Ki67 immunofluorescence. Immunofluorescence was per-
formed as described above. Primary antibody anti-Ki67 (NeoMar-
kers, Fremont, CA, USA) was used at a 1:200 dilution and secondary
antibody was used in a 1:200 dilution.
Fluorescence-activated cell sorter analysis. Cells were
cultured in six-well plates (2 105 cells/well) with 20 ng/ml
bFGF and with or without 1,25(OH)2D3 100 nM. After 16 or 22 h,
cells were trypsinized and fixed with 70% ethanol overnight at
41C. Ethanol was removed and cells were incubated in 1 mg/ml
RNase for 30 min at 371C, and then stained for 30 min with 50mg/ml
propidium iodide. Cell fluorescence distributions were
obtained using an Epics XL flow cytometer (Coulter, Fullerton,
CA, USA).
MTT analysis. VSMC were incubated with 1 mM VGA1102 for
24 h. Then, 100 ml of 0.5 g/l MTT solution was added. Cells were
incubated at 371C for 45–60 min, and thereafter, 100ml of 20%
sodium dodecyl sulfate in N,N-dimethylformamide:H2O 1:1 solu-
tion was added. Plates were incubated overnight at 371C and
absorbances were measured at 570 nm. The levels in the control
wells were designated as 100% viability.
Analysis of gene expression levels in VSMCs
Real-time PCR analysis. Total cellular RNA was extracted using
RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse transcrip-
tion was performed with a first-strand DNA synthesis Kit for reverse
transcriptase-PCR (Roche Diagnostics). We used the Taqman real-
time PCR method. The forward, reverse, and Taqman middle
primers for rat VEGF, VDR, FLT-1, FLK-1, and glyceraldehyde-3-
phosphate dehydrogenase were purchased from Applied Biosystems.
Each real-time PCR reaction was performed using 0.5 mg total RNA.
For reverse transcription, a 1 h period at 421C was run before
inactivating the reverse transcriptase at 991C for 10 min. Forty cycles
at 951C for 15 s and 601C for 1 min were performed with an ABI
Prism 7000 Sequence Detection System (Applied Biosystems). All
experiments were carried out three times; triplicate readings were
taken; and the average was calculated. The relative RNA amount was
calculated by standard formulae. Average and s.e. from three
experiments were calculated.
Western blot and ELISA analysis. Western blot analysis of cell
and aortic extracts were performed as described previously.50 We
used 20 mg of total protein per well or, in the case of FLT-1, 1 mg of
total protein was immunoprecipitated as described previously.51
After boiling 5 min in 1 loading buffer (0.06 M Tris-Cl, pH 6.8, 2%
sodium dodecyl sulfate, 10% glycerol, 5% b-mercaptoethanol,
0.002% bromophenol blue) samples were loaded in sodium dodecyl
sulfate gels. After running, transfer to polyvinylidine fluoride
membranes (Millipore), and blocking blots were incubated with
primary antibody for VDR (1:1000; Santa Cruz Biotechnology,
Santacruz, CA, USA), FLT-1 or FLK-1 (Neomarkers). After washing
with Tris-buffered saline with 0.1% Tween, horseradish peroxidase-
conjugated secondary antibody (1:12500; Amersham Biosciences,
Fairfield, CT, USA) was added for an extra hour. Binding was
detected with the ECLTM Advance Western Blotting Detection Kit
(Amersham Biosciences) and the VersaDoc Imaging system Model
4000 (BioRad). Signals were quantified with the Quantity One
software (BioRad, Hercules, CA, USA).
Levels of VEGF were determined in culture media supernatants
of control cells and cells treated with 1,25(OH)2D3 (100 nM) with a
commercially available enzyme-linked immunosorbent assay (R&D
Systems).
Statistical analysis
Differences between means of two groups were assessed by Student’s
t-test. For three or more groups, we performed a one-way analysis of
variance. A Po0.05 was considered statistically significant.
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